Positive association between 25-hydroxyvitamin D and C-reactive protein is confounded by hormonal contraceptive use

Journal of Women's Health

Volumn 22, Issue 5, 2013, Pages 417-425

  García Bailo, Bibiana ^a,b   Josse, Andrea R ^a   Jamnik, Joseph ^a   Badawi, Alaa ^b   El Sohemy, Ahmed ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; C REACTIVE PROTEIN; CONTRACEPTIVE AGENT; 25-HYDROXYVITAMIN D; BIOLOGICAL MARKER; ORAL CONTRACEPTIVE AGENT; VITAMIN D;

ADULT; ARTICLE; ASIAN; BLOOD ANALYSIS; CAUCASIAN; ETHNICITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MOLECULAR INTERACTION; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VITAMIN BLOOD LEVEL; ANALOGS AND DERIVATIVES; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CANADA; COMPARATIVE STUDY; ETHNOLOGY; FAR EAST; METABOLISM; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADULT; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CANADA; CONTRACEPTIVES, ORAL, HORMONAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FAR EAST; FEMALE; HUMANS; MALE; VITAMIN D; YOUNG ADULT;

EID: 84875938891     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2012.4046     Document Type: Article

References (43)

1. Badawi A, Klip A, Haddad P, et al. Type 2 diabetes mellitus and inflammation: Prospects for biomarkers of risk and nutritional intervention. Diabetes Metab Syndr Obes 2010; 3:173-186.
2. Multhoff G, Radons J. Radiation, inflammation, and immune responses in cancer. Front Oncol 2012;2:58.
3. Choy E. Understanding the dynamics: Pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2012;51 Suppl 5:v3-11.
4. Comabella M, Khoury SJ. Immunopathogenesis of multiple sclerosis. Clin Immunol 2012;142:2-8.
5. Bouillon R, Carmeliet G, Verlinden L, et al. Vitamin D and human health: Lessons from vitamin D receptor null mice. Endocr Rev 2008;29:726-776.
6. Lagishetty V, Liu NQ, Hewison M. Vitamin D metabolism and innate immunity. Mol Cell Endocrinol 2011;347:97-105.
7. Salekzamani S, Neyestani TR, avi-Majd H, et al. Is vitamin D status a determining factor for metabolic syndrome? A casecontrol study. Diabetes Metab Syndr Obes 2011;4:205-212.
8. Bellia A, Garcovich C, D'Adamo M, et al. Serum 25-hydroxyvitamin D levels are inversely associated with systemic inflammation in severe obese subjects. Intern Emerg Med 2013;8:33-40.
9. Shab-Bidar S, Neyestani TR, Djazayery A, et al. Improvement of vitamin D status resulted in amelioration of biomarkers of systemic inflammation in the subjects with type 2 diabetes. Diabetes Metab Res Rev 2012;28:424-430.
10. Neyestani TR, Nikooyeh B, avi-Majd H, et al. Improvement of vitamin D status via daily intake of fortified yogurt drink either with or without extra calcium ameliorates systemic inflammatory biomarkers, including adipokines, in the subjects with type 2 diabetes. J Clin Endocrinol Metab 2012; 97:2005-2011.
11. Jorde R, Sneve M, Torjesen PA, Figenschau Y, Goransson LG, Omdal R. No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine 2010;50:175-180.
12. Gepner AD, Ramamurthy R, Krueger DC, Korcarz CE, Binkley N, Stein JH. A prospective randomized controlled trial of the effects of vitamin d supplementation on cardiovascular disease risk. PLoS One 2012;7:e36617.
13. Amer M, Qayyum R. Relation between serum 25-hydroxyvitamin D and C-reactive protein in asymptomatic adults (from the continuous National Health and Nutrition Examination Survey 2001 to 2006). Am J Cardiol 2012;109:226-230.
14. Norman AW. From vitamin D to hormone D: Fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 2008;88:491S- 499S.
15. Wang Y, Jacobs EJ, McCullough ML, et al. Comparing methods for accounting for seasonal variability in a biomarker when only a single sample is available: Insights from simulations based on serum 25-hydroxyvitamin D. Am J Epidemiol 2009;170:88-94.
16. Nesby-O'Dell S, Scanlon KS, Cogswell ME, et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: Third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr 2002;76:187-192. (Pubitemid 34686565)
17. Wang TJ, Zhang F, Richards JB, et al. Common genetic determinants of vitamin D insufficiency: A genome-wide association study. Lancet 2010;376:180-188.
18. Gozdzik A, Barta JL, Weir A, et al. Serum 25-hydroxyvitamin d concentrations fluctuate seasonally in young adults of diverse ancestry living in toronto. J Nutr 2010;140:2213-2220.
19. Sowers MR, Wallace RB, Hollis BW, Lemke JH. Parameters related to 25-OH-D levels in a population-based study of women. Am J Clin Nutr 1986;43:621-628. (Pubitemid 16014849)
20. Harris SS, Dawson-Hughes B. The association of oral contraceptive use with plasma 25-hydroxyvitamin D levels. J Am Coll Nutr 1998;17:282-284. (Pubitemid 28265504)
21. Bouillon R, van BH, de MP. The measurement of the vitamin D-binding protein in human serum. J Clin Endocrinol Metab 1977;45:225-231. (Pubitemid 8162806)
22. Abbas S, Linseisen J, Slanger T, et al. Serum25-hydroxyvitaminD and risk of post-menopausal breast cancer:Results of a large casecontrol study. Carcinogenesis 2008;29:93-99. (Pubitemid 351201746)
23. Kwok S, Canoy D, Ashton WD, et al. Increased C-reactive protein levels in overweight and obese women taking exogenous hormones: The United Kingdom Women's Heart Study (UKWHS). Clin Endocrinol (Oxf) 2009;71:727-732.
24. Soska V, Fiala J, Nebeska K, Jarkovsky J, Hruba D. The atherogenic index of plasma is increased by hormonal contraception. Scand J Clin Lab Invest 2011;71:94-100.
25. Katayama H, Paczesny S, Prentice R, et al. Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. Genome Med 2009;1:47.
26. Pitteri SJ, Hanash SM, Aragaki A, et al. Postmenopausal estrogen and progestin effects on the serum proteome. Genome Med 2009;1:121.
27. Chlebowski RT, Anderson GL. Changing concepts: Menopausal hormone therapy and breast cancer. J Natl Cancer Inst 2012;104:517-527.
28. Dreon DM, Slavin JL, Phinney SD. Oral contraceptive use and increased plasma concentration of C-reactive protein. Life Sci 2003;73:1245-1252. (Pubitemid 36794589)
29. Josse AR, Garcia-Bailo B, Fischer K, El-Sohemy A. Novel effects of hormonal contraceptive use on the plasma proteome. PLoS One 2012;7:e45162.
30. Ding EL, Mehta S, Fawzi WW, Giovannucci EL. Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: Reanalysis of Women's Health Initiative randomized trial. Int J Cancer 2008;122:1690-1694. (Pubitemid 351413414)
31. Kluft C, Leuven JA, Helmerhorst FM, Krans HM. Pro-inflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment. Vascul Pharmacol 2002;39:149-154. (Pubitemid 36398240)
32. Garcia-Bailo B, Brenner DR, Nielsen D, et al. Dietary patterns and ethnicity are associated with distinct plasma proteomic groups. Am J Clin Nutr 2012;95:352-361.
33. Cahill L, Corey PN, El-Sohemy A. Vitamin C deficiency in a population of young Canadian adults. Am J Epidemiol 2009;170:464-471.
34. Fontaine-Bisson B, Wolever TM, Connelly PW, Corey PN, El-Sohemy A. NF-kappaB -94Ins/Del ATTG polymorphism modifies the association between dietary polyunsaturated fatty acids and HDL-cholesterol in two distinct populations. Atherosclerosis 2009;204:465-470.
35. Eny KM, Corey PN, El-Sohemy A. Dopamine D2 receptor genotype (C957T) and habitual consumption of sugars in a free-living population of men and women. J Nutrigenet Nutrigenomics 2009;2:235-242.
36. USDA National Nutrient Database for Standard Reference, Release 20. US Department of Agriculture Agricultural Research Service 2007. Available from: Www.ars.usda.gov/main/site- main.htm?modecode = 12-35-45-00. Accessed May 25, 2012.
37. Wang Y, Zhu J, DeLuca HF. Where is the vitamin D receptor? Arch Biochem Biophys 2012;523:123-133.
38. Ramagopalan SV,HegerA,BerlangaAJ, et al.AChIP-seqdefined genome-wide map of vitamin D receptor binding: Associations with disease and evolution. Genome Res 2010;20:1352-1360.
39. Williams JK. Rationale for new oral contraceptive dosing. Int J Fertil Womens Med 2004;49:30-35. (Pubitemid 38337896)
40. Buchanan JR, Santen R, Cauffman S, Cavaliere A, Greer RB, Demers LM. The effect of endogenous estrogen fluctuation on metabolism of 25-hydroxyvitamin D. Calcif Tissue Int 1986;39:139-144. (Pubitemid 16039684)
41. Schwartz B, Smirnoff P, Shany S, Liel Y. Estrogen controls expression and bioresponse of 1,25-dihydroxyvitamin D receptors in the rat colon. Mol Cell Biochem 2000;203:87-93. (Pubitemid 30111780)
42. Lechner D, Bajna E, Adlercreutz H, Cross HS. Genistein and 17beta-estradiol, but not equol, regulate vitamin D synthesis in human colon and breast cancer cells. Anticancer Res 2006;26:2597-2603. (Pubitemid 44155540)
43. Gagnon C, Baillargeon JP, Desmarais G, Fink GD. Prevalence and predictors of vitamin D insufficiency in women of reproductive age living in northern latitude. Eur J Endocrinol 2010;163:819-824.